ASTH vs AZN: fair value comparison
Astrana Health, Inc. and AstraZeneca PLC · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AZN currently sits closer to the top of our discount ranking. AZN carries the stronger quality grade.
| ASTH | AZN | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $35.91 | $156.93 |
| 12-month range | $22.32–$49.81 | $156.06–$202.39 |
| Sector rank | #7 of 113 Healthcare | #6 of 113 Healthcare |
| Quality grade | D | B |
| Momentum grade | — | A |
| Leverage | High | Moderate |
| Margin trend | — | Expanding |
| Revenue growth | — | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| DCF cross-check | — | Undervalued |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: ASTH fair value analysis · AZN fair value analysis